Daily Cardiology Research Analysis
Three papers stand out today: a mechanobiology study shows an epicardial patch can lower left-ventricular wall stress and reverse stress-induced PIEZO1 upregulation after myocardial infarction; a Cell Reports Medicine study reveals a hepato-cardiac FGF21 signaling axis that drives pressure-overload hypertrophy via cardiomyocyte FGF21; and an updated meta-analysis of randomized trials in ACS with anemia finds liberal transfusion reduces myocardial infarction but increases acute lung injury, with
Summary
Three papers stand out today: a mechanobiology study shows an epicardial patch can lower left-ventricular wall stress and reverse stress-induced PIEZO1 upregulation after myocardial infarction; a Cell Reports Medicine study reveals a hepato-cardiac FGF21 signaling axis that drives pressure-overload hypertrophy via cardiomyocyte FGF21; and an updated meta-analysis of randomized trials in ACS with anemia finds liberal transfusion reduces myocardial infarction but increases acute lung injury, with no overall MACE difference.
Research Themes
- Mechanotransduction and device-based myocardial repair
- Endocrine-autocrine signaling in cardiac hypertrophy (FGF21 axis)
- Transfusion thresholds in acute coronary syndromes with anemia
Selected Articles
1. Reversal of Stress-Induced PIEZO1 Elevation with Mechanically Adapted Epicardial Patch for Myocardial Infarction Treatment.
A stress-shielding elastomeric epicardial patch designed via finite element analysis reduced LV wall stress after MI, reversed stress-induced chromatin opening at the Piezo1 promoter, normalized PIEZO1 expression, and restored contractile gene programs. Therapeutic benefit correlated with PIEZO1 reversal and was validated in a porcine model; sustained PIEZO1 overexpression blunted efficacy, confirming a mechanistic role beyond structural support.
Impact: This study introduces a device-based, mechanobiology-guided strategy to reverse a pathogenic mechanosensor (PIEZO1) and favorably remodel the post-MI heart, with validation in both rodent and large-animal models.
Clinical Implications: If translated, mechanically adapted epicardial patches could complement guideline-directed medical therapy post-MI by reducing wall stress and targeting PIEZO1-dependent remodeling. PIEZO1 may serve as a biomarker to select responders or as a therapeutic target in device-drug combinations.
Key Findings
- Elastomeric epicardial patches reduced LV wall stress after MI and mitigated remodeling (finite element–guided design).
- Patch therapy suppressed stress-induced chromatin opening at the Piezo1 promoter, reversing PIEZO1 elevation and restoring contractile gene expression.
- Therapeutic benefits were reproduced in a porcine model; enforced high PIEZO1 expression partially abrogated patch efficacy, confirming a causal mechanism.
Methodological Strengths
- Cross-species validation (rat MI and porcine model) with concordant molecular and functional endpoints.
- Mechanistic dissection linking biomechanical unloading to epigenomic regulation (chromatin accessibility) and PIEZO1 expression.
Limitations
- Preclinical study; human safety, durability, and procedural feasibility are untested.
- Long-term effects on arrhythmia risk and scar maturation were not reported.
Future Directions: First-in-human feasibility and safety trials, optimization of patch mechanics and delivery, and combination approaches targeting PIEZO1 signaling with pharmacotherapy.
Elevated expression of the mechanosensitive ion channel PIEZO1 in response to abnormal mechanical stimuli is implicated in many diseases, including myocardial infarction (MI). However, no effective strategy is currently available to normalize PIEZO1 expression for disease management. This study investigates the therapeutic potential of mechanically adapted cardiac patches in reversing PIEZO1 elevation and treating MI. Increased mechanical stress and PIEZO1 upregulation are observed in ischemic cardiomyopathy myocardium. Using finite element analysis, elastomeric patches are designed and applied on MI rats to reduce left ventricular (LV) wall stress and mitigate LV remodeling. Molecular analysis reveals that patch treatment suppresses stress-induced chromatin opening of the Piezo1 promoter, reversing PIEZO1 elevation and restoring heart contraction gene expression. The patch's therapeutic benefits correlate with the reversal of PIEZO1 elevation is further validated in a porcine model. Notably, constant high expression of endogenous PIEZO1 partially blocks the patch's therapeutic effects, confirming that the mechanism of patch treatment involves reversing PIEZO1 expression, in addition to providing physical support. In conclusion, cardiac patches reduce LV wall stress, preserving cardiac function and geometry by both physically supporting and biologically reversing PIEZO1 expression, highlighting the potential of medical devices in normalizing PIEZO1 expression and treating related diseases.
2. Mitochondrial NNT Promotes Diastolic Dysfunction in Cardiometabolic HFpEF.
Using strain-specific single-nucleus transcriptomics and functional genetics, the study implicates mitochondrial nicotinamide nucleotide transhydrogenase (NNT) as a driver of diastolic dysfunction in a cardiometabolic HFpEF model. The work shows how NNT-dependent metabolic signaling and Fgf1 are pathophysiologic nodes, highlighting mitochondrial dysfunction as a targetable axis in HFpEF.
Impact: It provides a mechanistic explanation for variability in HFpEF models and identifies mitochondrial NNT and Fgf1 as potentially druggable targets, opening avenues for disease-modifying therapies.
Clinical Implications: While preclinical, these findings prioritize mitochondrial redox coupling via NNT as a therapeutic axis in HFpEF and caution that genetic background (e.g., NNT deficiency) can alter preclinical readouts—important for translational study design.
Key Findings
- Strain-specific single-nucleus transcriptomics implicated mitochondrial oxidative pathways and NNT in cardiomyocytes as central to diastolic dysfunction in a cardiometabolic HFpEF model.
- NNT and Fgf1 emerged as mechanistic nodes, suggesting targetable pathways for HFpEF therapy.
- The study explains attenuated diastolic dysfunction in C57BL/6J mice due to an NNT loss-of-function background, informing model selection.
Methodological Strengths
- Single-nucleus transcriptomics with strain-specific analysis linking genotype to phenotype.
- Mechanistic inference around mitochondrial redox coupling and signaling nodes (NNT, Fgf1).
Limitations
- Preclinical; absence of interventional pharmacology validating NNT/Fgf1 targeting in large animals or humans.
- Abstract truncation limits detailed methodological appraisal (e.g., exact experimental numbers, timelines).
Future Directions: Develop small-molecule or gene-targeting strategies against NNT/Fgf1, validate in large-animal HFpEF models, and test biomarkers of mitochondrial redox coupling in human HFpEF cohorts.
BACKGROUND: Clinical management of heart failure with preserved ejection fraction (HFpEF) is hindered by a lack of disease-modifying therapies capable of altering its distinct pathophysiology. Despite the widespread implementation of a 2-hit model of cardiometabolic HFpEF to inform precision therapy, which utilizes HFD+L-NAME (ad libitum high-fat diet and 0.5% N[ω]-nitro-L-arginine methyl ester), we observe that C57BL6/J mice exhibit less cardiac diastolic dysfunction in response to HFD+L-NAME. METHODS: Genetic strain-specific single-nucleus transcriptomic analysis identified disease-relevant genes that enrich oxidative metabolic pathways within cardiomyocytes. Because C57BL/6J mice are known to harbor a loss-of-function mutation affecting the inner mitochondrial membrane protein CONCLUSIONS: Together, these findings underscore the pivotal role of mitochondrial dysfunction in HFpEF pathogenesis, implicating both NNT and Fgf1 as novel therapeutic targets.
3. Liberal versus restrictive red blood cell transfusion strategy in acute coronary syndrome and anemia: an updated systematic review and meta-analysis.
Across 5 RCTs (4,510 patients), liberal transfusion in ACS with anemia reduced myocardial infarction risk but increased acute lung injury, with no significant difference in MACE versus restrictive strategies. The findings support individualized transfusion thresholds and the need for large confirmatory trials.
Impact: This RCT-based meta-analysis directly informs bedside transfusion thresholds in ACS, balancing ischemic benefit (MI reduction) against pulmonary harm (acute lung injury).
Clinical Implications: For ACS with anemia, a liberal transfusion approach may lower MI risk but at the cost of more acute lung injury; clinicians should individualize thresholds (considering ischemia, hypoxemia, and pulmonary risk) pending results of large definitive RCTs.
Key Findings
- Five RCTs (n=4,510) comparing liberal vs restrictive RBC transfusion in ACS with anemia were synthesized.
- Liberal transfusion reduced myocardial infarction but increased acute lung injury; no significant difference in MACE or other clinical outcomes.
- Heterogeneity of thresholds underscores the need for standardized, large multicenter RCTs (PROSPERO: CRD42024506844).
Methodological Strengths
- Restriction to randomized controlled trials enhances internal validity.
- Protocol registration (PROSPERO) and contemporary literature search across major databases.
Limitations
- Potential heterogeneity in transfusion thresholds, co-interventions, and outcome definitions across trials.
- Trial-level (not patient-level) meta-analysis limits subgroup explorations and interaction assessments.
Future Directions: Conduct adequately powered multicenter RCTs with standardized thresholds and pulmonary safety endpoints; explore precision strategies integrating ischemic burden and lung injury risk.
BACKGROUND: It is uncertain whether a liberal red blood cell (RBC) transfusion strategy is superior to a restrictive approach in patients with acute coronary syndrome (ACS) and anemia. METHODS: We searched MEDLINE, Embase, the Cochrane Library, and ClinicalTrials.gov from inception to April 2024 for randomized controlled trials (RCTs) comparing liberal and restrictive transfusion strategies in ACS patients with concurrent anemia. RESULTS: Five RCTs (4,510 patients) were included in this meta-analysis. There was no significant difference between the liberal and restrictive RBC transfusion strategy groups in the risk of major adverse cardiovascular events (MACE) (RR 0.91, 95% CI: 0.68-1.21; CONCLUSIONS: Our meta-analysis demonstrated that a liberal RBC transfusion strategy reduced the risk of MI and increased the risk of acute lung injury but did not affect other clinical outcomes compared to a restrictive approach in patients with mainly acute MI and anemia. New large-scale multicenter RCTs are required to confirm or refute our findings and provide more reliable results. SYSTEMATIC REVIEW REGISTRATION: PROSPERO (CRD42024506844).